Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice

Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice

Abstract Background The association between cardiac complications, such as heart failure (HF), and chronic kidney disease (CKD) is well known. In this study, we examined the effectiveness and safety of treatment with neprilysin inhibition in patients with advanced chronic kidney disease (stage 3b-4)...

Full description

Bibliographic Details
Main Authors:	María Dolores Martínez-Esteban, Teresa Vázquez-Sánchez, Rafael Pozo-Álvarez, Alicia Moreno-Ortiz, Juana Alonso-Titos, Guillermo Martín-Reyes, Pedro Ruiz-Esteban, Daniel Gaitán-Román, Domingo Hernández
Format:	Article
Language:	English
Published:	BMC 2022-08-01
Series:	BMC Nephrology
Subjects:	Chronic kidney disease Heart failure Reduced ejection fraction Neprilysin inhibitor Glomerular filtration rate
Online Access:	https://doi.org/10.1186/s12882-022-02919-z

Similar Items

Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease—A Real-World Experience
by: Sara C. Pereira, et al.
Published: (2023-02-01)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
by: Domingo Pascual-Figal, et al.
Published: (2021-11-01)

The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients
by: Ji‐Hye Oh, et al.
Published: (2022-08-01)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
by: Margherita Ilaria Gioia, et al.
Published: (2022-06-01)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
by: Mi‐Gil Moon, et al.
Published: (2021-06-01)

Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction
by: April F. Mohanty, et al.
Published: (2021-10-01)

Use and Out‐of‐Pocket Cost of Sacubitril‐Valsartan in Patients With Heart Failure
by: Supriya Shore, et al.
Published: (2022-09-01)

Association between sacubitril/valsartan initiation and real‐world health status trajectories over 18 months in heart failure with reduced ejection fraction
by: Merrill Thomas, et al.
Published: (2021-08-01)

Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction
by: Jeffrey S. Tran, et al.
Published: (2021-04-01)

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
by: Javad Habibi, et al.
Published: (2019-03-01)

Potential of valsartan+sacubitril therapy in hypertensive heart disease
by: A. G. Ovchinnikov, et al.
Published: (2021-08-01)

Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure
by: Sheldon E. Litwin, et al.
Published: (2022-12-01)

Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)
by: Andrea Di Lenarda, et al.
Published: (2023-01-01)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
by: Sarah L Anderson, et al.
Published: (2018-08-01)

Sacubitril/Valsartan Shows Improvement of the Cardio-Ankle Vascular Index in a Hypertensive Patient
by: Shimizu K, et al.
Published: (2023-08-01)

Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure
by: Klaus K. Witte, et al.
Published: (2023-02-01)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022-08-01)

Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
by: Juan Carlos López‐Azor, et al.
Published: (2019-12-01)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
by: Muhammad Nauman Khan, et al.
Published: (2023-03-01)

The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Sharath Kommu, et al.
Published: (2024-03-01)

Penalized Model‐Based Unsupervised Phenomapping Unravels Distinctive HFrEF Phenotypes With Improved Outcomes Discrimination From Sacubitril/Valsartan Treatment Independent of MAGGIC Score
by: Kuo‐Tzu Sung, et al.
Published: (2023-09-01)

Is Sacubitril/Valsartan Able to Change the Timing for Implantation of Cardiac Devices in Heart Failure with Reduced Ejection Fraction?
by: Marta Afonso Nogueira, et al.
Published: (2022-08-01)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
by: Ying Ding, et al.
Published: (2023-12-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan
by: Sokos GG, et al.
Published: (2020-01-01)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
by: Katie L. Peppin, et al.
Published: (2020-01-01)

Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan
by: Iacopo Fabiani, et al.
Published: (2023-10-01)

A per‐protocol initiation of sacubitril/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region
by: Bassam Atallah, et al.
Published: (2019-08-01)

The role of sacubitril/valsartan in the management of cardiac resynchronization therapy non‐responders: a retrospective analysis
by: Kyeong‐Hyeon Chun, et al.
Published: (2020-12-01)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
by: Lars H. Lund, et al.
Published: (2022-02-01)

Sacubitril/valsartan attenuates atrial conduction disturbance and electrophysiological heterogeneity with ameliorating fibrosis in mice
by: Satoshi Iwamiya, et al.
Published: (2024-01-01)

Pharmacoutilization and adherence to sacubitril/valsartan in real world: the REAL.IT study in HFrEF
by: Massimo Iacoviello, et al.
Published: (2024-02-01)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
by: Aldo P. Maggioni, et al.
Published: (2022-12-01)

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
by: Pei Yang, et al.
Published: (2022-08-01)

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
by: Yandrapalli S, et al.
Published: (2017-10-01)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
by: Valeria Visco, et al.
Published: (2022-10-01)

Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP‐HF registry
by: Yevgeniy Khariton, et al.
Published: (2021-02-01)

Combined drug sacubitril/valsartan -a new era of treatment of chronic heart failure
by: V. S. Nikiforov
Published: (2020-10-01)

Does sacubitril/valsartan work in children with heart failure?—a pilot study
by: Yahe Xu, et al.
Published: (2023-11-01)

Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease
by: Chih‐Yuan Niu, et al.
Published: (2022-09-01)